Please Note: Medical Necessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

PRIOR AUTHORIZATION **BYPASS**

Opsumit® (macitentan)

Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

Name _____

Address _____

℞

MD _____

Signature _____

Name _____

Address _____

℞ epoprostenol 1.5mg
quantity #90 vials
sig: Intravenous infusion

as directed by physician

Dx: PULMONARY HYPERTENSION

ICD 10: I 27.2

MD _____

Signature _____

SAMPLE

usDoctor

Prescriber Information

Last Name:	First Name
DEA/NPI:	Specialty:
Phone - -	Fax - -

Member Information

Last Name:	First Name
Member ID Number	DOB: - -

Medication Information:

Drug Name and Strength:	Quantity and Dosing:
Diagnosis:	Duration:

When advised below, please include all requested fax documentation (lab results, etc.) when submitting this Prior Authorization fax form; not submitting requested documentation could delay the clinical review process.

Letairis Prior Authorization Form

You must answer ALL of the following questions		
1. Is Letairis being prescribed by a pulmonologist, cardiologist, nephrologist, or rheumatologist?	Y	N
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1)?	Y	N
4. Does the patient have one of the following causes for pulmonary arterial hypertension (PAH)? **(Please Circle)** • Idiopathic/Primary PAH • Drugs and toxin induced • Connective tissue disease (e.g., Lupus/SLE, RA scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease) • HIV infection • Portal hypertension • Congenital heart disease • Schistosomiasis • Chronic hemolytic anemia	Y	N
5. Does the patient experience WHO Functional Class II through IV symptoms?	Y	N

6. Does the patient's cardiac catheterization report meet any of the following? **(Please Circle)** • MPAP 25 mmHg or greater + PCWP less than 19 mmHg/LVEDP not reported • MPAP 25 mmHg or greater + LVEDP less than 19 mmHg/PCWP not reported • MPAP 25 mmHg or greater + PCWP less than 19 mmHg + LVEDP less than 19 mmHg *Note: MPAP=Mean pulmonary arterial pressure; PCWP=Pulmonary wedge pressure at end expiration; LVEDP=Left ventricular end diastolic pressure on direct measurement.* *Please provide a copy of the report.*	Y	N
7. Is the patient enrolled in the Letairis REMS Program?	Y	N

Tracleer Prior Authorization Form

You must answer ALL of the following questions		
1. Is Tracleer being prescribed by a pulmonologist, cardiologist, nephrologist, or rheumatologist?	Y	N
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1)?	Y	N
4. Does the patient have one of the following causes for pulmonary arterial hypertension (PAH)? **(Please Circle)** • Idiopathic/Primary PAH • Drugs and toxin induced • Connective tissue disease (e.g., Lupus/SLE, RA scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease) • HIV infection • Portal hypertension • Congenital heart disease • Schistosomiasis • Chronic hemolytic anemia	Y	N
5. Does the patient experience WHO Functional Class II through IV symptoms?	Y	N
6. Does the patient's cardiac catheterization report meet any of the following? **(Please Circle)** • MPAP 25 mmHg or greater + PCWP less than 19 mmHg/LVEDP not reported • MPAP 25 mmHg or greater + LVEDP less than 19 mmHg/PCWP not reported • MPAP 25 mmHg or greater + PCWP less than 19 mmHg + LVEDP less than 19 mmHg *Note: MPAP=Mean pulmonary arterial pressure; PCWP=Pulmonary wedge pressure at end expiration; LVEDP=Left ventricular end diastolic pressure on direct measurement.* *Please provide a copy of the report.*	Y	N
7. Is the patient enrolled in the Tracleer Access Program (TAP)?	Y	N

Opsumit Prior Authorization Form

You must answer ALL of the following questions		
1. Is Opsumit being prescribed by a pulmonologist, cardiologist, nephrologist, or rheumatologist?	Y	N
2. Is the patient 18 years of age or older?	Y	N
3. Does the patient have a diagnosis of pulmonary arterial hypertension (WHO Group 1)?	Y	N

4. Does the patient have one of the following causes for pulmonary arterial hypertension (PAH)? **(Please Circle)** • Idiopathic/Primary PAH • Drugs and toxin induced • Connective tissue disease (e.g., Lupus/SLE, RA scleroderma, systemic sclerosis, CREST syndrome, polymyositis, polyarteritis nodosa, mixed connective tissue disease) • HIV infection • Portal hypertension • Congenital heart disease • Schistosomiasis • Chronic hemolytic anemia	Y	N
5. Does the patient experience WHO Functional Class II through IV symptoms?	Y	N
6. Does the patient's cardiac catheterization report meet any of the following? **(Please Circle)** • MPAP 25 mmHg or greater + PCWP less than 19 mmHg/LVEDP not reported • MPAP 25 mmHg or greater + LVEDP less than 19 mmHg/PCWP not reported • MPAP 25 mmHg or greater + PCWP less than 19 mmHg + LVEDP less than 19 mmHg *Note: MPAP=Mean pulmonary arterial pressure; PCWP=Pulmonary wedge pressure at end expiration; LVEDP=Left ventricular end diastolic pressure on direct measurement.* *Please provide a copy of the report.*	Y	N
7. Is the patient enrolled in the Opsumit REMS program?	Y	N

Please note, not all drugs/diagnoses are covered on all plans.

Comments: _____

Information given on this form is accurate as of this date.

Prior Authorization forms are located on the Cover Page. Print a new form for each request as forms are updated periodically.

_____ _____

Prescriber or Authorized Signature **Date**

_____

Authorized Medical Staff – Name/Title

Attention Healthcare Provider: If you would like to discuss this request with a medical professional, please contact the Prior Authorization Department whose numbers appear on the Cover Page.

I understand that USDoctor's use or disclosure of individually identifiable health information, whether furnished by me or obtained by another source such as medical providers, shall be in accordance with federal privacy regulations under HIPAA (Health Insurance Portability and Accountability Act of 1996).

usDoctor

Contact Information:

Telephone: (855)251.9116
Fax: (248)593.9575

Please Note: Medical Necessity Prior Authorization may be utilized to override both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager.

PRIOR AUTHORIZATION FORM:
COVER PAGE

MEMBER INFORMATION			
First Name		**Last Name**	
Plan			
Member ID		**Date of Birth**	

DRUG INFORMATION			
Drug Name			
Quantity		**ICD-10**	
Directions		**Duration of Therapy**	
Diagnosis			

PLEASE LIST ALTERNATIVE THERAPIES THAT HAVE BEEN ATTEMPTED AND ANY OTHER PERTINENT INFORMATION RELATED TO DRUG AND/OR DISEASE STATE. IF NOT PRESENT, WITHIN NORMAL LIMITS WILL BE USED FOR THE REVIEW.

Medication/Failure Reason:

IgE:_____

ESR:_____ **CRP:**_____ **# Joints:**_____ **%BSA:**_____

Height:_____ **Weight:**_____ **BMI:**_____

HA1C:_____ **Hemoglobin:**_____ **Hematocrit:**_____ **T-Score:**_____

Dialysis:_____ **Long Term Care Facility:**_____ **Self Injecting:**_____

Stimulation test:_____/_____ **Growth velocity:**_____ **#Chemotherapy cycles/month:**_____

Mini-Mental Status Test:_____ **Baseline Free testosterone/Total testosterone:**_____/_____

HCV RNA viral load:_____ **Viral Genotype:**_____ **ALT:**_____

PHYSICIAN INFORMATION			
Physician Signature		**Date**	
Physician Name		**NPI #**	
Phone Number		**Fax Number**	
Action Needed	Only mark Urgent when standard review time would seriously harm the member's life or health or ability to regain maximum function ☐ Urgent ☐ For Review	**Pharmacy Fax**	

The information contained in this facsimile message, including the attachments, may be privileged, may constitute inside information and is intended only for use of the addressee. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited and may be unlawful. If you have received this communication in error, please immediately notify me by replying to this message and destroy the original message.